Fate Therapeutics Reports Year-End 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Fate Therapeutics (FATE) Tops Q4 EPS by 1c
March 12, 2015 5:00 PM EDTFate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
... More